123 375

Cited 0 times in

CYP2D6 Inhibitory Activities of Sarpogrelate hydrochloride and Drug-Drug Interaction

Other Title
Sarpogrelate hydrochloride의 CYP2D6 억제 효과와 약물-약물 상호작용
Authors
조, 두연
Department
대학원 의학과
Degree
Doctor (2015)
Abstract
Sarpogrelate has inhibitory effects on serotonin-induced platelet aggregation, thrombus formation, vasoconstriction and vascular smooth muscle cell proliferation, all of which are mediated by 5-HT2A receptors, and consequently reduces the ischemic symptoms associated with peripheral artery disease. Despite the wide use and excellent pharmacological actions of sarpogrelate, to date there is no information regarding the potential inhibitory effects of sarpogrelate and M-1 (an active metabolite of sarpogrelate) on CYP isoforms or drug–drug interactions.

Using a cocktail assay, the effects of sarpogrelate and M-1 on nine CYP isoforms were measured by specific marker reactions in human liver microsomes. Nine healthy male subjects genotyped for CYP2D6*1/*1 or *1/*2 were included in a randomized, open-label, three-treatment three-period, crossover study. A single oral dose of metoprolol (100 mg) was administered with water (treatment A) and sarpogrelate (100 mg bid.; a total dose of 200 mg; treatment B), or after pretreatment of sarpogrelate for 3 days (100 mg tid.; treatment C). Plasma levels of metoprolol and α-hydroxymetoprolol were determined using a validated liquid chromatography–tandem mass spectrometry (LC-MS/MS) method. Changes in heart rate and blood pressure were monitored as pharmacodynamic responses to metoprolol.

Sarpogrelate potently and selectively inhibited CYP2D6-mediated dextromethorphan O-demethylation with an IC50 (Ki) value of 3.05 μM (1.24 μM), in a competitive manner. M-1 also markedly inhibited CYP2D6 activity; its inhibitory effect with an IC50 (Ki) value of 0.201 μM (0.120 μM) was more potent than that of sarpogrelate. Co-administration of sarpogrelate increased the area under the plasma concentration–time curve from time zero to the last measurement (AUCt) of metoprolol increased by 53% (geometric mean ratio [GMR], 1.53; 90% confidence interval [CI], 1.09–2.32) and by 51% (1.51; 1.04–2.30), respectively. Similar patterns were observed for the increase in Cmax of metoprolol induced by sarpogrelate. However, the pharmacodynamics of metoprolol did not differ significantly among the three treatment groups.

Sarpogrelate and M-1 were potent and selective competitive inhibitors of CYP2D6 in vitro. Especially, inhibition of CYP2D6 by M-1 was ten-fold more potent than that of sarpogrelate. Sarpogrelate weakly inhibited a sensitive CYP2D6 substrate, metoprolol, by increasing metoprolol exposure by less than two-fold, but sarpogrelate had few effects on the pharmacodynamics of metoprolol. Higher systemic exposure to metoprolol if co-administered with sarpogrelate is not expected to be clinically meaningful. Extrapolation of these results to clinical practice suggests that no special monitoring is necessary if administering sarpogrelate with sensitive CYP2D6 substrates.
Keywords
SarpogrelateCYP2D6 inhibitionDrug-Drug interactionMetoprololPharmacokineticsPharmacodynamicsCYP2D6 억제약물-약물 상호작용약동학약력학
Appears in Collections:
Theses > School of Medicine / Graduate School of Medicine > Doctor
AJOU Authors
조, 두연
Full Text Link
Files in This Item:
000000018795.pdfDownload
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse